Antibodies.com Moves to Expanded UK Headquarters

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Antibodies.com, a provider of biological reagents for research purposes, announced on Aug. 4, 2025 that it is moving its headquarters to an expanded location in Cambridge Technopark, United Kingdom. The new facility is 5000 square feet, five times larger than the company’s previous location, and includes increased operational capabilities. The move comes as a result of the company’s growth over the past five years. According to a press release (1), it has tripled its customer base to 5000 research institutions worldwide.

The new site has advanced laboratory space, a logistics area for enhanced inventory management, and expanded research and development capabilities. The facility will be able to streamline workflows and strengthen order fulfillment.

“We are proud to take this significant step forward with our new Cambridge headquarters,” Stewart Newlove, CTO and co-founder of Antibodies.com, said in the press release. “This move positions us at the center of the global life sciences community and will enable us to enhance the excellent service our customers have come to expect, scale with global demand, and continue supporting innovation in the discovery and development of antibody therapeutics.”

Antibodies.com has more than 100,000 products, including primary and secondary antibodies, proteins, and enzyme-linked immunosorbent assay (ELISA) kits, used by researchers in more than 100 countries. The company has facilities in Cambridge, UK; Stockholm, Sweden; and St. Louis, United States.

Research advances innovation

In other research-related news, in June 2025, the Massachusetts Institute of Technology (MIT) and Recursion, a clinical-stage biotech company, released a next-generation biomolecular foundation model, Boltz-2 that can predict molecular structure and binding affinity, two critical factors in drug discovery and development workflows (2).

“Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail," said Najat Khan, chief R&D officer and chief commercial officer at Recursion, in a press release at the time (2). “By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds."

In July 2025, scientists from MIT, the University of California Santa Barbara, Integrated Biosciences, Illumina Ventures, and Princeton University identified compounds that could be used as antivirals to fight multiple viruses (3). The compounds activated a defense pathway inside host cells called the integrated stress response pathway in a screen of nearly 400,000 molecules.

“We’re very excited about this work, which allows us to harness the stress response of the host cells to arrive at a means to identify and develop broad-spectrum antivirals,” said James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering, in a press release (3).

References

1. Antibodies.com. Antibodies.com Expands UK Headquarters with New 5x Larger Facilities in Cambridge to Accommodate Rapid Growth. Press Release. Aug. 4, 2025.
2. Recursion. MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy. Press Release. June 6, 2025.
3. MIT. Scientists Discover Compounds That Help Cells Fight a Wide Range of Viruses. Press Release. July 14, 2025. https://news.mit.edu/2025/scientists-discover-compounds-helping-cells-fight-wide-range-viruses-0714